Geographic Atrophy

The first approved GA treatment leaves room for additional therapies.

According to the company, GATHER-2 24-month results met the primary objective of reducing the rate of GA growth in patients treated with IZERVAY compared to sham.

The complement C5 inhibitor significantly reduced GA progression.

You may be wondering: What is all this hype about geographic atrophy (GA)? If you are, let us look at the enigma.

According to the company, the therapeutic is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two phase 3 clinical trials.

Data from the 30 month GALE extension study indicated that continuous treatment with pegcetacoplan injection showed increasing beneficial effects over that timeframe in patients with geographic atrophy (GA).

The company has completed evaluation on candidates and selected a single drug candidate to move forward into clinical trials.

A single, consistent modality leads to better geographic atrophy tracking.

CT1812 is an experimental, oral therapy for the treatment of geographic atrophy secondary to dry age-related macular edema.

Clinical benefit of complement inhibition has been demonstrated in clinical trials, but there are possible consequences to consider.

How to diagnose and monitor progression.

Diagnose, monitor, comanage—optometrists support patients throughout all stages of the disease.

The GA Won’t Wait campaign is designed to help older adults and their families understand and recognize the symptoms of this progressive and irreversible disease.

Catch up on what happened in optometry during the week of April 17-April 21.

One way to advance the current understanding of GA is to study how disease progression varies among related individuals.

A look back on what happened in optometry during the week of April 10-April 14.

Pegcetacoplan’s recent FDA approval creates an option for patients with dry AMD.

A look back on what happened in optometry during the week of April 3-April 7.

Imaging can elucidate visual prognosis and disease progression risk.

These disorders account for most of the vision loss in working-age and elderly Americans.

Following the submission of the 24-month phase 3 data in November 2022, Apellis received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD.

Look out for at-risk patients and prepare to establish treatment protocols.

The submission of 24-month efficacy data from DERBY and OAKS is classified as a Major Amendment to the New Drug Application, which delays the PDUFA target action date until February 2023.

Latest data from phase 3 studies finds increased effects over time with intravitreal pegcetacoplan for geographic atrophy secondary to age-related macular degeneration.

If approved, pegcetacoplan—an investigational, targeted C3 therapy—will be the first-ever treatment for GA.

Advancements enable better diagnosis, treatment of patients.

A decision by the FDA is expected in August 2022.

A look at the latest developments in retinal disease, including clinical trials and advanced therapies.

New detailed, longer-term findings were presented at the 2022 ARVO meeting.